DDIT3 and diffuse large B-cell lymphoma: Further studies with high resolution array comparative genomic hybridization (aCGH) have revealed recurrent copy number alterations (CNA), as well as prognostic indicators in a number of DLBCL subtypes[22-27], for example, in a recent high resolution CGH study, CNA resistant to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy included amplifications of 1p36.13, 1q42.3, 3p21.31, 7q11.23 and 16p13.3, as well as losses at 9p21.3 and 14p21.31 in DLBCL.